The translational potential of this combination is strengthened by the growing identification of oncogenic mutations in HRAS, KRAS (HGNC IDs 5173, 6407), NRAS and BRAF (HGNC ID 1097) genes in SS cell lines and clinical tumor subsets [68, 102, 103, 106]. The gene discussed is HRAS; the disease is neoplasm.